Amgen said it’s “very encouraged” by interim Phase 2 data for its obesity drug, quickly sparking investor interest. Here are the burning questions surrounding Amgen’s MariTide.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
